Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-728mR T-Cells in HIV
NCT02388594Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- Apr 2015
- Primary completion
- Sep 2018
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of SB-728mR-HSPC in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of Pennsylvania. Primary endpoint: Number of participants with adverse events at 6 months. Started Apr 2015; status: completed.
02
Drugs
SB-728mR-HSPC
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02388594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02388594.